Glucowin-M 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in reduced blood glucose levels. The prolonged-release formulation of Glucowin-M 1 ensures sustained drug release, promoting stable plasma concentrations and improving patient compliance through once-daily dosing. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or monotherapy. Glucowin-M 1 should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia due to the sulfonylurea component. Regular monitoring of blood glucose and periodic assessment of renal function are recommended during therapy. Glucowin-M 1 Tablet PR should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize risks.